
Protein regulator may lead to new multiple sclerosis treatments.
Zepatier can be used with or without ribavirin and does not require interferon.
Adherence patterns and other risk factors predict increased utilization of acute care by outpatients with cancer pain.
Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.
Research addresses whether the prior authorization process creates a barrier to timely and effective care for hepatitis C.
Nearly 1 of 4 initial requests for Harvoni were denied in a recent study of hepatitis C drug coverage.
NASP addresses what defines a specialty pharmacy and specialty medications.
Comprehensive medication management programs may improve drug adherence across multiple chronic conditions.
Men diagnosed with cancer under age 25 far less likely to have children and more likely to take infertility drugs.
Charlie Sheen's announcement that he is HIV-positive may lead to a new era of HIV preventative efforts.
Several chemotherapy agents have been investigated for neoadjuvant use in HER2-positive breast cancer.
Less than half of adolescents and young adults who survive Hodgkin lymphoma receive recommended services within the first year after treatment.
Sites and apps such as Grindr, Manhunt, Scruff, Adam4Adam, and Craigslist may be linked with higher STD incidences.
Zepatier is approved for the treatment of patients with chronic hepatitis C virus genotypes 1 and 4.
Mergers and acquisitions among pharmacy benefit managers may help limit medication cost hikes.
Researchers created a model framework to compare costs of 7 common regimens to treat relapsed and/or refractory multiple myeloma.
Viekirax and Exviera combination showed promising results in the treatment of patients with chronic HCV genotype 1b with compensated cirrhosis.
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses methods specialty pharmacies can use to help patients access high cost medications.
Combination of sialidase and cucurbitacin I shows substantial antitumor activity in sarcoma therapy.
Drugs like Viagra could improve insulin sensitivity and secretion without diminishing fibrinolytic function.
Toll-like receptor 4 behave differently on psoriasis skin compared with uninvolved skin.
Top stories of the week on The American Journal of Pharmacy Benefits.
The combined impact of anti-cancer treatments and exercise holds promise for shrinking tumors.
Recent advances and updates in oncology and cancer drug development.
Prior studies have found that Rac1 is a molecule that maintains chronic neuropathic pain resulting from injury to the nervous system.
Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.
High doses of biotin show promise in progressive multiple sclerosis.
Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.
Gazyva plus bendamustine provides a new option to significantly reduce the risk of death.
The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.